Prediagnosis aspirin use and outcomes in a prospective cohort of esophageal cancer patients

Therapeutic Advances in Gastroenterology

Volumn 9, Issue 6, 2016, Pages 806-814

  Araujo, James L ^a   Altorki, Nasser K ^b   Sonett, Joshua R ^a   Rodriguez, Adriana ^a   Sungur Stasik, Kivilcim ^a   Spinelli, Cathy F ^b   Neugut, Alfred I ^a   Abrams, Julian A ^a  

^a Department of Medicine   (United States)

^b WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

aspirin; epidemiology; esophageal cancer; metastasis; survival

Indexed keywords

ACETYLSALICYLIC ACID; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ALL CAUSE MORTALITY; ARTICLE; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EXPOSURE; DRUG USE; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS CANCER; ESOPHAGUS SURGERY; FEMALE; FOLLOW UP; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; METASTASIS FREE SURVIVAL; METASTASIS POTENTIAL; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; TERTIARY HEALTH CARE; TREATMENT DURATION;

EID: 84992187690     PISSN: 1756283X     EISSN: 17562848     Source Type: Journal    
DOI: 10.1177/1756283X16657985     Document Type: Article

References (32)

1. Bastiaannet E., Sampieri K., Dekkers O., De Craen A., Van Herk-Sukel M., Lemmens V., et al. (2012) Use of aspirin postdiagnosis improves survival for colon cancer patients. Br J Cancer 106: 1564-1570.
2. Bhandari P., Bateman A., Mehta R., Stacey B., Johnson P., Cree I., et al. (2006) Prognostic significance of cyclooxygenase-2 (COX-2) expression in patients with surgically resectable adenocarcinoma of the oesophagus. BMC Cancer 6: 134.
3. Brasky T., Baik C., Slatore C., Alvarado M., White E., (2012) Prediagnostic nonsteroidal anti-inflammatory drug use and lung cancer survival in the vital study. J Thorac Oncol 7: 1503-1512.
4. Buskens C., Van Rees B., Sivula A., Reitsma J., Haglund C., Bosma P., et al. (2002) Prognostic significance of elevated cyclooxygenase 2 expression in patients with adenocarcinoma of the esophagus. Gastroenterology 122: 1800-1807.
5. Chan A., Ogino S., Fuchs C., (2009) Aspirin use and survival after diagnosis of colorectal cancer. JAMA 302: 649-658.
6. Charlson M., Pompei P., Ales K., Mackenzie C., (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40: 373-383.
7. Coghill A., Newcomb P., Campbell P., Burnett-Hartman A., Adams S., Poole E., et al. (2011) Prediagnostic non-steroidal anti-inflammatory drug use and survival after diagnosis of colorectal cancer. Gut 60: 491-498.
8. Edge S., Byrd D., Compton C., Fritz A., Greene F., Trotti A., (2010) AJCC Cancer Staging Manual. 7th edition. New York: Springer-Verlag.
9. Fink S., Yamauchi M., Nishihara R., Jung S., Kuchiba A., Wu K., et al. (2014) Aspirin and the risk of colorectal cancer in relation to the expression of 15-hydroxyprostaglandin dehydrogenase (HPGD). Sci Transl Med 6: 233re2.
10. Fraser D., Sullivan F., Thompson A., McCowan C., (2014) Aspirin use and survival after the diagnosis of breast cancer: a population-based cohort study. Br J Cancer 111: 623-627.
11. Heath E., Canto M., Piantadosi S., Montgomery E., Weinstein W., Herman J., et al. (2007) Secondary chemoprevention of Barrett's esophagus with celecoxib: results of a randomized trial. J Natl Cancer Inst 99: 545-557.
12. Howlader N., Ries L., Mariotto A., Reichman M., Ruhl J., Cronin K., (2010) Improved estimates of cancer-specific survival rates from population-based data. J Natl Cancer Inst 102: 1584-1598.
13. Jimenez P., Piazuelo E., Cebrian C., Ortego J., Strunk M., Garcia-Gonzalez M., et al. (2010) Prostaglandin Ep2 receptor expression is increased in Barrett's oesophagus and oesophageal adenocarcinoma. Aliment Pharmacol Ther 31: 440-451.
14. Li L., Zhao J., Wu Z., Wang G., Chen G., (2009) Meta-analysis: clinicopathological and prognostic significance of cyclooxygenase-2 expression on oesophageal squamous cell carcinoma. Aliment Pharmacol Ther 30: 589-596.
15. Li Y., Brasky T., Nie J., Ambrosone C., McCann S., Shields P., et al. (2012) Use of nonsteroidal anti-inflammatory drugs and survival following breast cancer diagnosis. Cancer Epidemiol Biomarkers Prev 21: 239-242.
16. Liao L., Vaughan T., Corley D., Cook M., Casson A., Kamangar F., et al. (2012a) Nonsteroidal anti-inflammatory drug use reduces risk of adenocarcinomas of the esophagus and esophagogastric junction in a pooled analysis. Gastroenterology 142: 442-452, e445, quiz e422-443.
17. Liao X., Lochhead P., Nishihara R., Morikawa T., Kuchiba A., Yamauchi M., et al. (2012b) Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med 367: 1596-1606.
18. Liu J., Jamieson G., Wu T., Zhang S., Wang Q., Drew P., (2006) Cyclooxygenase-2 expression in squamous cell carcinoma of the esophagus. Dis Esophagus 19: 350-354.
19. McCowan C., Munro A., Donnan P., Steele R., (2013) Use of aspirin Postdiagnosis in a cohort of patients with colorectal cancer and its association with all-cause and colorectal cancer specific mortality. Eur J Cancer 49: 1049-1057.
20. Mehta R., Song M., Bezawada N., Wu K., Garcia-Albeniz X., Morikawa T., et al. (2014) A prospective study of macrophage inhibitory cytokine-1 (MIC-1/GDF15) and risk of colorectal cancer. J Natl Cancer Inst 106: dju016.
21. Morris C., Armstrong G., Bigley G., Green H., Attwood S., (2001) Cyclooxygenase-2 expression in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence. Am J Gastroenterol 96: 990-996.
22. Nishihara R., Lochhead P., Kuchiba A., Jung S., Yamauchi M., Liao X., et al. (2013) Aspirin use and risk of colorectal cancer according to BRAF mutation status. JAMA 309: 2563-2571.
23. Rothwell P., Fowkes F., Belch J., Ogawa H., Warlow C., Meade T., (2011) Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 377: 31-41.
24. Sarfati D., Blakely T., Pearce N., (2010) Measuring cancer survival in populations: relative survival vs cancer-specific survival. Int J Epidemiol 39: 598-610.
25. Siegel R., Naishadham D., Jemal A., (2012) Cancer statistics, 2012. CA Cancer J Clin 62: 10-29.
26. Takatori H., Natsugoe S., Okumura H., Matsumoto M., Uchikado Y., Setoyama T., et al. (2008) Cyclooxygenase-2 expression is related to prognosis in patients with esophageal squamous cell carcinoma. Eur J Surg Oncol 34: 397-402.
27. Thrift A., Nagle C., Fahey P., Smithers B., Watson D., Whiteman D., (2012) Predictors of survival among patients diagnosed with adenocarcinoma of the esophagus and gastroesophageal junction. Cancer Causes Control 23: 555-564.
28. Thun M., Namboodiri M., Calle E., Flanders W., Heath C., (1993) Aspirin use and risk of fatal cancer. Cancer Res 53: 1322-1327.
29. Trivers K., De Roos A., Gammon M., Vaughan T., Risch H., Olshan A., et al. (2005) Demographic and lifestyle predictors of survival in patients with esophageal or gastric cancers. Clin Gastroenterol Hepatol 3: 225-230.
30. Tsibouris P., Hendrickse M., Isaacs P., (2004) Daily use of non-steroidal anti-inflammatory drugs is less frequent in patients with Barrett's oesophagus who develop an oesophageal adenocarcinoma. Aliment Pharmacol Ther 20: 645-655.
31. Van Staalduinen J., Frouws M., Reimers M., Bastiaannet E., Van Herk-Sukel M., Lemmens V., et al. (2016) The effect of aspirin and nonsteroidal anti-inflammatory drug use after diagnosis on survival of oesophageal cancer patients. Br J Cancer 114: 1053-1059.
32. Zell J., Ziogas A., Bernstein L., Clarke C., Deapen D., Largent J., et al. (2009) Nonsteroidal anti-inflammatory drugs: effects on mortality after colorectal cancer diagnosis. Cancer 115: 5662-5671.